NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

I only have one posting a day, so I can't do much "answering", but I'll try to give you an explanation.

I know the use of emojis come of one-dimensional, but I will tell why I used them and obviously a little to quick, so you took it as me not recognizing the truthfulness of the information. And I DO recognize it. I have just seen it before and when one digs deeper, one finds its just a part of a simple pump and dump scam and if one looks even deeper, that stuff is happening at the foundation, that is real nasty. But I guess all longs here are aware.

I acted upon your "ai ai ai ai ai", because I am not agreeing with the sentiment of that outburst. I don't believe there is a competition and there won't be.

I believe NovoCure is a sinking ship. A wounded animal, fighting for delaying it going down. That the management a long time ago have realized that and the whole "operation" is all about squeezing pump and dump money out of it, as long as they can.

Single Stock have been showing how that works out and we have all witnessed earlier, how they have acquired themselves cheap shares at discount prices, then pumped some news and then a week later we all got to know the state of affairs.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174538023
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174476512
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174321031

Looking at how openly this pump and dump scam goes on and on, it is mind blowing, there haven't been an investigation or a lawsuit yet.

If we for a moment even try to discard the knowledge of NVCR having "manipulated their results" looking better in the past, the primary outcome measure for the METIS trial is time to intracranial progression. This falls under the category of progression-free survival (PFS).

Here's why:

Primary Outcome Measure: The text explicitly states "Time to intracranial progression" as the primary outcome measure with a time frame of 3 years.
Progression-Free Survival: PFS focuses on how long a patient lives without the cancer worsening in a specific area (intracranial in this case). This aligns with the "time to intracranial progression" metric.

While overall survival (OS) is listed as a secondary outcome measure, the primary focus of the METIS trial is on progression-free survival.

Overall survival (OS) takes a longer time to determine as it measures how long patients live after starting treatment. While OS data might be collected and reported as a secondary endpoint later, PFS is often the primary endpoint in cancer trials due to the time it takes to gather conclusive OS data, which is why OS is the gold standard.

But that's one thing. Let's look at real life. This is from the last quarter, how many active patients the TTF device (Optune helmet) has world wide. You can go back a year at a time and compare the statistics. It just doesn't look like this will "take off". In the US the figure is going down. .



I assert, that gbm patients - or other cancer patients - are only interested in using the TTF device, if no better alternatives are around. Better ... meaning treatments where there are actually possibilities of curing people and which do not restrict them in living an active life without constantly being reminded of their illness.

The TTF device is a "strap-on for life" solution. Shave your head, wear it 18-24 hours a day and pay $21.000 a month for it. Well thats the last figure available from 2016 anyway. And if lucky, it will keep those cancer cells "at bay".

So no wonder the whole army of affiliated NVCR doctors have been trying to put obstacles before DCvax-L for years now. And yes ... we HAVE been able to find out, that many of the voices who've been used to downtalk DCVax-L results, have either worked with Optune, have Optune clinics or have not disclosed their interests of having ties with NVCR.

Just look at Matt, who's arguments were torn to pieces by Al Musella. Matt is an Optune Clinics king in England. Safe to say, he can see what approval of DCvax-L means to him.



We know that the ONLY journal/site, who passed on Adam Feuersteins lying hit piece from May 2022, was AACRJournals and we know AACR have been giving NovoCure a lot of research, cancer and development awards.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169535600

And then we have the whole army of paid bashers on NWBO stock boards, of which we know MANY have had and do have NVCR interests. Instead of posting on NVCR board though, you will find them here.

Yesterday HyGro came out of hibernation, just due to a negative comment of NVCR. He needs to push positives for it. The same it was with JonDoeUK. You found these guys selling crazy also on the SeekingAlpha and Benzinga comment sections, while constantly bashing NWBO. We all know there are quite a few more here, who are NVCR enthusiasts.

The bottomline is, the days of TTF devices are neigh, due to dendritic cells heading for the spotlight. DCVax-L is the biggest competitor and with approval of it, there will be no incentive - at least regarding glioblastoma - to use the device, unless some wants to go with a combo treatment. But we already know that adding poly-iclc and later on keytruda, that will completely annihilate the need for TTF.

It is not a cure. It is a possible treatment due to lack of alternatives, and that is why, an army of pawns have been trying to put obstacles in front of alternatives.

We can only guess, if this has connections to market makers spoofing.

Because HOW does NVCR manage to pump the share price successively constantly and then dump again?

That was an explanation of my "intent" with the use of the two emojis.